This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.
The Zacks Analyst Blog Highlights: Home Depot, Glaxo, Marriott, DISH and O'Reilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Glaxo, Marriott, DISH and O'Reilly
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.
Foreign Stock Roundup: TOT, STO & GSK Earnings Impress, BP & SNY Disappoint
by Swarup Gupta
Global stocks were weighed down by massive losses and heightened volatility on Wall Street last week.
Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.
Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up
by Zacks Equity Research
Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.
Glaxo (GSK) Stock Down Despite Q4 Earnings and Sales Beat
by Zacks Equity Research
Glaxo's (GSK) Q4 earnings and revenue beat estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.
Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.
Is TransDigm (TDG) Poised for Another Earnings Beat in Q1?
by Zacks Equity Research
We expect TransDigm (TDG) to beat on first-quarter fiscal 2018 earnings, driven by bullish momentum in its proprietary engineered products business.
Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might lead the company to an earnings beat in Q4.
Will Tinder & PMC Growth Aid Match Group (MTCH) Q4 Earnings?
by Zacks Equity Research
Match Group's (MTCH) fourth-quarter 2017 earnings results to benefit from steady market traction of apps like Tinder, which are driving higher paid-member count.
AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
by Zacks Equity Research
AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.
Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion
by Zacks Equity Research
The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.
Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?
by Zacks Equity Research
J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.
Inovio's Influenza Vaccine Shows Potential, Shares Rally
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.
J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve
by Zacks Equity Research
J&J (JNJ) beat estimates for earnings while missing the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.
Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?
by Zacks Equity Research
J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.
J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.
J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What's Up?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in Q3 is likely to continue in Q4. Strong pharma performance and contribution from acquisitions should support the top line.
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?
by Zacks Equity Research
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.
Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?
by Zacks Equity Research
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
by Zacks Equity Research
Glaxo's (GSK) influenza vaccine ??? Fluarix Quadrivalent receives FDA approval for label expansion.
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
by Zacks Equity Research
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
by Zacks Equity Research
Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.